Please ensure Javascript is enabled for purposes of website accessibility

Why Lexicon Pharmaceuticals Stock Soared Today

By Evan Niu, CFA – Apr 27, 2020 at 4:24PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech company reported better-than-expected first-quarter results and now sees lower costs in 2020.

What happened

Shares of Lexicon Pharmaceuticals (LXRX) have soared today, closing out the session with gains of 12%, after the company reported first-quarter earnings results. The biotech beat expectations for both the top and bottom lines.

So what

Revenue in the first quarter declined 13% to $8 million, which was slightly ahead of the consensus estimate of $7.8 million. That translated into a net loss of $66.6 million, or $0.63 per share. Analysts were modeling for $0.69 per share in red ink. The biotech company's Xermelo, which treats carcinoid syndrome diarrhea, is seeing growth and represents the vast majority of revenue.

Close-up of a microscope next to vials in a stand

Image source: Getty Images.

"We achieved 17% growth in XERMELO net sales for the first quarter of 2020 compared to the prior-year period, and we see favorable growth dynamics going forward," CEO Lonnel Coats said in a statement. "We have made good progress on our pipeline, having fully enrolled the first efficacy cohort of 20 patients in the Phase 2 telotristat ethyl study in biliary tract cancer from which we expect top-line data later this year."

Now what

Lexicon laid out several milestones on the horizon, including the initiation of a phase 2 study for LX9211 in diabetic peripheral neuropathic pain that is expected in mid-2020. The company is expected to get data on the aforementioned phase 2 study of telotristat ethyl in biliary tract cancer in the fourth quarter.

Lexicon also adjusted certain parts of its 2020 guidance. On the conference call with analysts, CFO Jeffrey Wade said the company was lowering its operating expense outlook for the year to a range of $235 million to $255 million, down from the prior forecast of $245 million to $275 million. Research and development expenses are also expected to be lower at $180 million to $190 million, compared to earlier guidance of $190 million to $210 million.

Evan Niu, CFA has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Lexicon Pharmaceuticals Stock Quote
Lexicon Pharmaceuticals
LXRX

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.